Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Jul 1;365(Pt 1):57–67. doi: 10.1042/BJ20011297

New insights into heparin binding to vitronectin: studies with monoclonal antibodies.

P Anne Underwood 1, Alan Kirkpatrick 1, Sue M Mitchell 1
PMCID: PMC1222657  PMID: 12071840

Abstract

Vitronectin is a plasma glycoprotein that binds to a variety of ligands. There is considerable debate regarding the dependency of these binding interactions upon the conformational status of vitronectin, the role of multimerization and how the binding of different ligands can change vitronectin's conformational state. We have developed a method of capturing vitronectin directly from fresh plasma using solid-phase monoclonal antibodies. Various biotin-labelled secondary monoclonal antibodies were used to quantify the bound vitronectin and to measure its degree of denaturation. Using these tools we demonstrated that one monoclonal antibody partially denatured vitronectin without direct multimerization. Treatment of vitronectin in plasma with soluble heparin produced a similar degree of denaturation. These results led to a proposed adaptation of the unfolding/refolding pathways for chemically denatured vitronectin originally presented by Zhuang and co-workers in 1996 [Zhuang, Blackburn and Peterson (1996) J. Biol. Chem. 271, 14323-14332 and Zhuang, Li, Williams, Wagner, Seiffert and Peterson (1996) J. Biol. Chem. 271, 14333-14343]. The adapted version allows for the production of a more stable partially unfolded intermediate, resulting from the binding of particular ligands. We also demonstrated that the avidity of heparin binding to vitronectin is governed by both the conformational state of the monomer and multimerization of the molecule.

Full Text

The Full Text of this article is available as a PDF (236.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bale M. D., Wohlfahrt L. A., Mosher D. F., Tomasini B., Sutton R. C. Identification of vitronectin as a major plasma protein adsorbed on polymer surfaces of different copolymer composition. Blood. 1989 Dec;74(8):2698–2706. [PubMed] [Google Scholar]
  2. Barnes D. W., Reing J. E., Amos B. Heparin-binding properties of human serum spreading factor. J Biol Chem. 1985 Aug 5;260(16):9117–9122. [PubMed] [Google Scholar]
  3. Barnes D. W., Silnutzer J. Isolation of human serum spreading factor. J Biol Chem. 1983 Oct 25;258(20):12548–12552. [PubMed] [Google Scholar]
  4. Bittorf S. V., Williams E. C., Mosher D. F. Alteration of vitronectin. Characterization of changes induced by treatment with urea. J Biol Chem. 1993 Nov 25;268(33):24838–24846. [PubMed] [Google Scholar]
  5. Boyd N. A., Bradwell A. R., Thompson R. A. Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice. J Clin Pathol. 1993 Nov;46(11):1042–1045. doi: 10.1136/jcp.46.11.1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dahlbäck B., Podack E. R. Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry. 1985 Apr 23;24(9):2368–2374. doi: 10.1021/bi00330a036. [DOI] [PubMed] [Google Scholar]
  7. François P. P., Preissner K. T., Herrmann M., Haugland R. P., Vaudaux P., Lew D. P., Krause K. H. Vitronectin interaction with glycosaminoglycans. Kinetics, structural determinants, and role in binding to endothelial cells. J Biol Chem. 1999 Dec 31;274(53):37611–37619. doi: 10.1074/jbc.274.53.37611. [DOI] [PubMed] [Google Scholar]
  8. Hayashi M., Akama T., Kono I., Kashiwagi H. Activation of vitronectin (serum spreading factor) binding of heparin by denaturing agents. J Biochem. 1985 Oct;98(4):1135–1138. doi: 10.1093/oxfordjournals.jbchem.a135363. [DOI] [PubMed] [Google Scholar]
  9. Høgåsen K., Mollnes T. E., Harboe M. Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. J Biol Chem. 1992 Nov 15;267(32):23076–23082. [PubMed] [Google Scholar]
  10. Izumi M., Yamada K. M., Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta. 1989 Feb 24;990(2):101–108. doi: 10.1016/s0304-4165(89)80019-4. [DOI] [PubMed] [Google Scholar]
  11. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  12. Liang O. D., Rosenblatt S., Chhatwal G. S., Preissner K. T. Identification of novel heparin-binding domains of vitronectin. FEBS Lett. 1997 Apr 28;407(2):169–172. doi: 10.1016/s0014-5793(97)00330-x. [DOI] [PubMed] [Google Scholar]
  13. Morris C. A., Underwood P. A., Bean P. A., Sheehan M., Charlesworth J. A. Relative topography of biologically active domains of human vitronectin. Evidence from monoclonal antibody epitope and denaturation studies. J Biol Chem. 1994 Sep 23;269(38):23845–23852. [PubMed] [Google Scholar]
  14. Preissner K. T., Müller-Berghaus G. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin. J Biol Chem. 1987 Sep 5;262(25):12247–12253. [PubMed] [Google Scholar]
  15. Preissner K. T., Müller-Berghaus G. S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin. Eur J Biochem. 1986 May 2;156(3):645–650. doi: 10.1111/j.1432-1033.1986.tb09626.x. [DOI] [PubMed] [Google Scholar]
  16. Preissner K. T., Wassmuth R., Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J. 1985 Oct 15;231(2):349–355. doi: 10.1042/bj2310349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Seiffert D., Ciambrone G., Wagner N. V., Binder B. R., Loskutoff D. J. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem. 1994 Jan 28;269(4):2659–2666. [PubMed] [Google Scholar]
  18. Seiffert D. Evidence that conformational changes upon the transition of the native to the modified form of vitronectin are not limited to the heparin binding domain. FEBS Lett. 1995 Jul 10;368(1):155–159. doi: 10.1016/0014-5793(95)00630-r. [DOI] [PubMed] [Google Scholar]
  19. Seiffert D., Loskutoff D. J. Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo. J Biol Chem. 1996 Nov 22;271(47):29644–29651. doi: 10.1074/jbc.271.47.29644. [DOI] [PubMed] [Google Scholar]
  20. Seiffert D., Schleef R. R. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood. 1996 Jul 15;88(2):552–560. [PubMed] [Google Scholar]
  21. Seiffert D. The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin. J Biol Chem. 1997 Apr 11;272(15):9971–9978. doi: 10.1074/jbc.272.15.9971. [DOI] [PubMed] [Google Scholar]
  22. Stockmann A., Hess S., Declerck P., Timpl R., Preissner K. T. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem. 1993 Oct 25;268(30):22874–22882. [PubMed] [Google Scholar]
  23. Tomasini B. R., Mosher D. F. Conformational states of vitronectin: preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea. Blood. 1988 Sep;72(3):903–912. [PubMed] [Google Scholar]
  24. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Underwood P. A., Bean P. A., Mitchell S. M., Whitelock J. M. Specific affinity depletion of cell adhesion molecules and growth factors from serum. J Immunol Methods. 2001 Jan 1;247(1-2):217–224. doi: 10.1016/s0022-1759(00)00327-6. [DOI] [PubMed] [Google Scholar]
  26. Yoneda A., Kojima K., Matsumoto I., Yamamoto K., Ogawa H. Porcine vitronectin, the most compact form of single-chain vitronectin: the smallest molecular mass among vitronectins was ascribed to deletion and substitution of base pairs, and proteolytic trimming of the peptide. J Biochem. 1996 Nov;120(5):954–960. doi: 10.1093/oxfordjournals.jbchem.a021512. [DOI] [PubMed] [Google Scholar]
  27. Yoneda A., Ogawa H., Kojima K., Matsumoto I. Characterization of the ligand binding activities of vitronectin: interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochemistry. 1998 May 5;37(18):6351–6360. doi: 10.1021/bi972247n. [DOI] [PubMed] [Google Scholar]
  28. Zhuang P., Blackburn M. N., Peterson C. B. Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem. 1996 Jun 14;271(24):14323–14332. doi: 10.1074/jbc.271.24.14323. [DOI] [PubMed] [Google Scholar]
  29. Zhuang P., Chen A. I., Peterson C. B. Native and multimeric vitronectin exhibit similar affinity for heparin. Differences in heparin binding properties induced upon denaturation are due to self-association into a multivalent form. J Biol Chem. 1997 Mar 14;272(11):6858–6867. doi: 10.1074/jbc.272.11.6858. [DOI] [PubMed] [Google Scholar]
  30. Zhuang P., Li H., Williams J. G., Wagner N. V., Seiffert D., Peterson C. B. Characterization of the denaturation and renaturation of human plasma vitronectin. II. Investigation into the mechanism of formation of multimers. J Biol Chem. 1996 Jun 14;271(24):14333–14343. doi: 10.1074/jbc.271.24.14333. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES